Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial

Ünal, Murat; Sevim, Serhan; Doğu, Okan; Vayısoğlu, Yusuf; Kanık, Arzu

doi:10.1080/00016489.2003.11720744

Cited by 43 publications

(65 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results showed that typical AR symptoms, such as rhinorrhea, nasal itching and sneezing, were relieved following BTX-A treatment. Our study further demonstrated that the severity of rhinorrhea was significantly diminished in the AR + BTX-A group compared with the AR group, being in accordance with the recent exploratory clinical treatment in patients with AR [12] .…”

Section: Discussionsupporting

confidence: 74%

See 1 more Smart Citation

Botulinum Toxin Therapy in the Ovalbumin-Sensitized Rat

Wen¹,

Yuan

Wang³

et al. 2007

Neuroimmunomodulation

View full text Add to dashboard Cite

Objective: The aim of this study was to determine whether intranasal administration of botulinum toxin type A (BTX-A) could relieve the typical symptoms of allergic rhinitis (AR) and alter substance P (SP)- and vasoactive intestinal peptide (VIP)-immunoreactive (IR) expression in nasal mucosa of AR animals sensitized with ovalbumin (OVA). Methods: AR was induced by intraperitoneal injection of OVA followed by its repeated intranasal instillation in female Wistar rats. Some AR animals were intranasally treated with a cotton strip containing BTX-A (10 U per nostril) for 1 h. After BTX-A treatment, OVA was repeatedly instilled in AR and AR + BTX-A groups every 2 days for 10 days. Subsequently, nasal symptoms were evaluated, and nasal secretions collected. Finally, the nasal mucosae of all animals were prepared for histological and immunohistochemical assessment. Results: BTX-A administration alleviated typical AR symptoms including rhinorrhea, nasal itching and sneezing, and subsequent intranasal repeated challenge with OVA did not trigger AR symptoms. After BTX-A treatment, inflammatory histological characteristics within the nasal mucosa of AR animals were absent, but atrophy of serous glands was observed. BTX-A decreased dense SP-IR and VIP-IR cells and fibers within and beneath the epithelium, around blood vessels and close to serous glands in AR animals. Conclusion: Local BTX-A treatment is an effective method to reduce AR symptoms. BTX-A decreased the excessive SP-IR and VIP-IR expression induced by OVA. Therefore, BTX-A may affect the nasal mucosa via the suppression of neuropeptides, playing a major role in autonomous mucosal innervation in the pathophysiology of AR.

show abstract

Section: Discussionsupporting

confidence: 74%

“…A recent test of BTX-A in AR patients has demonstrated that BTX-A could relieve rhinorrhea, nasal obstruction and sneezing [12] . BTX-A is well known to inhibit acetylcholine (ACh) release from cholinergic nerves in skeletal muscles [13] .…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin Therapy in the Ovalbumin-Sensitized Rat

Wen¹,

Yuan

Wang³

et al. 2007

Neuroimmunomodulation

View full text Add to dashboard Cite

show abstract

“…Allergan, bezogen. In einer Arbeit zeigte sich kein relevanter Unterschied zwischen den Behandlungsgruppen mit jeweils 20 und 30 Einheiten pro Nasenseite [27]. Als eigene klinische Erfahrung ist daher ein individuelles Herantasten der jeweiligen Dosis notwendig, wobei wir bei hö-heren Dosen sowohl injizierten als auch die Schwämmchen einlegten, um den Ablauf in den Nasopharynx bei höheren Volumina zu vermeiden.…”

Section: Introductionunclassified

“…Wie bei den anderen Botulinumtoxinindikationen ist auch hier zu beachten, dass bei fehlender oder zu geringer Wirkung die erneute Behandlung erst nach mehreren Wochen wieder erfolgen sollte, um die immunologischen Boosterphänomene zur Antikörperbil-dung zu reduzieren. Während die nasale Hyper sekretion und der Niesreiz zumeist gut ansprechen, gibt es zur nasalen Obstruktion widersprüchliche Ergebnisse [22,27]. Bei den unterschiedlichen Effekten in den Studien sind die Patientenselektion (allergisch vs. nichtallergisch), Dosierungsmengen und Applikationsformen zu beachten.…”

Section: Introductionunclassified

Botulinumtoxin für die Behandlung sekretorischer Störungen im Kopf-Hals-Bereich

Steffen

2012

HNO

View full text Add to dashboard Cite

Botulinum toxin can be used for the temporary blockade of secretory glands in the head and neck area. Botulinum toxin is increasingly the therapy of choice for the treatment of Frey's syndrome and gustatory tearing, and it is gaining attention for hypersalivation therapy. For nasal hypersecretion, this drug has a very specific use. In comparison to the treatment of skeletal muscles, the individual effect and its duration are more difficult to predict. All indications presented here are for off-label use; therefore, careful counseling and informed consent are necessary. With botulinum toxin, for several diseases, as new treatment options are opening up, well-founded knowledge about the indications and treatment course is important for the ENT surgeon.

show abstract

“…The results were significantly better in patients treated with botulinum toxin, especially in rhinorrhoea, nasal obstruction and sneezing. In selected cases, the injection of intranasal toxin botulinum may help control allergic rhinitis symptoms (Unal et al, 2003).…”

Section: Therapeutic Developments In the Treatment Of Allergic Rhinitmentioning

confidence: 99%

Treatment of Allergic Rhinitis: Anticholinergics, Glucocorticotherapy, Leukotriene Antagonists, Omalizumab and Specific-Allergen Immunotherapy

Palomo¹,

Bobolea²,

Gonzalez³

et al. 2012

Otolaryngology

View full text Add to dashboard Cite

Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double-blind, Placebo-controlled Clinical Trial

Abstract: In selected cases, injection of 40 units of BTX-A into the turbinates, as a single agent, may help the symptomatic control of AR for up to 8 weeks.

Cited by 43 publications

References 14 publications

Botulinum Toxin Therapy in the Ovalbumin-Sensitized Rat

Botulinum Toxin Therapy in the Ovalbumin-Sensitized Rat

Botulinumtoxin für die Behandlung sekretorischer Störungen im Kopf-Hals-Bereich

Treatment of Allergic Rhinitis: Anticholinergics, Glucocorticotherapy, Leukotriene Antagonists, Omalizumab and Specific-Allergen Immunotherapy

Contact Info

Product

Resources

About